Ceribell Reports Third Quarter 2025 Financial Results
CeriBell, Inc. (CBLL)
Company Research
Source: GlobeNewswire
SUNNYVALE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended September 30, 2025. Third Quarter 2025 & Recent Highlights Reported total revenue of $22.6 million in the third quarter of 2025, a 31% increase compared to the same period in 2024Achieved gross margin of 88% compared to 87% for the same period in 2024 Ended the quarter with 615 total active accounts Appointed Erica Rogers to the Board of Directors “We are encouraged by our third quarter performance, which reflects strong commercial execution and continued momentum in adoption of the Ceribell System,” said co-founder and CEO Jane Chao, Ph.D. “Looking ahead, our focus remains on generating robust clinical evidence to help establish point-of-care EEG as a new standard of care for seizure management in t
Show less
Read more
Impact Snapshot
Event Time:
CBLL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CBLL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CBLL alerts
High impacting CeriBell, Inc. news events
Weekly update
A roundup of the hottest topics
CBLL
News
- Ceribell Receives FDA 510(k) Clearance for Use of Clarity? Algorithm for NeonatesGlobeNewswire
- Ceribell to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumGlobeNewswire
- CeriBell (NASDAQ:CBLL) had its price target lowered by analysts at JPMorgan Chase & Co. from $21.00 to $17.00. They now have an "overweight" rating on the stock.MarketBeat
- CeriBell (NASDAQ:CBLL) had its price target lowered by analysts at TD Cowen from $36.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
CBLL
Earnings
- 11/4/25 - Beat
CBLL
Sec Filings
- 12/4/25 - Form 144
- 12/4/25 - Form 4
- 12/3/25 - Form 4
- CBLL's page on the SEC website